Candel Therapeutics, Inc. (CADL)

Candel Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	102.65	35.41	70.06	82.64	35.05
Cash & Short-Term Investments	102.65	35.41	70.06	82.64	35.05
Cash Growth	189.88%	-49.45%	-15.23%	135.76%	-22.20%
Prepaid Expenses	1.15	1.38	1.89	2.3	0.09
Total Current Assets	103.8	36.8	71.95	84.95	35.15
Property, Plant & Equipment	2.73	4.02	5.48	3.84	2.79
Other Long-Term Assets	0.33	0.38	0.27	0.42	0.35
Total Assets	106.87	41.2	77.69	89.21	38.28
Accounts Payable	0.24	0.42	0.38	1.59	0.92
Accrued Expenses	4.72	3.96	4.72	3.44	3.14
Short-Term Debt	-	-	-	-	0.46
Current Portion of Long-Term Debt	9.9	8.89	-	-	-
Current Portion of Leases	0.57	0.51	0.46	-	-
Other Current Liabilities	22.11	0.4	0.05	0.33	0.19
Total Current Liabilities	37.53	14.18	5.62	5.36	4.71
Long-Term Debt	2.6	12.38	20.85	0.56	0.48
Long-Term Leases	0.41	0.97	1.49	-	-
Long-Term Unearned Revenue	-	-	0.14	-	0.13
Other Long-Term Liabilities	-	0.92	1.88	19.15	7.46
Total Liabilities	40.54	28.46	29.98	25.07	12.78
Common Stock	0.47	0.29	0.29	0.29	0.12
Additional Paid-In Capital	258.51	149.93	146.96	144.15	20.49
Retained Earnings	-192.21	-137.03	-99.09	-80.3	-44.17
Treasury Stock	-0.45	-0.45	-0.45	-	-
Total Common Equity	66.33	12.75	47.71	64.14	-23.56
Shareholders' Equity	66.33	12.75	47.71	64.14	25.5
Total Liabilities & Equity	106.87	41.2	77.69	89.21	38.28
Total Debt	13.47	22.76	22.8	0.56	0.95
Net Cash (Debt)	89.18	12.65	47.26	82.08	34.11
Net Cash Growth	604.95%	-73.23%	-42.43%	140.66%	-23.59%
Net Cash Per Share	2.82	0.44	1.64	4.35	2.94
Filing Date Shares Outstanding	47.24	29.35	28.92	28.69	11.64
Total Common Shares Outstanding	46.81	29.09	28.92	28.69	11.64
Working Capital	66.28	22.61	66.33	79.58	30.43
Book Value Per Share	1.42	0.44	1.65	2.24	-2.03
Tangible Book Value	66.33	12.75	47.71	64.14	-23.56
Tangible Book Value Per Share	1.42	0.44	1.65	2.24	-2.03
Machinery	2.16	2.19	2.5	1.19	1.4
Construction In Progress	-	-	-	-	1.22
Leasehold Improvements	3.11	3.11	3.06	2.99	0.31

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q